Sung Lee | Senior Vice President of Investor Relations |
Daniel O'Day | Chairman & Chief Executive Officer |
Robin Washington | Executive Vice President & Chief Financial Officer |
Johanna Mercier | Chief Commercial Officer |
Diana Brainard | Senior Vice President, HIV & Emerging Viral Infections |
John Sundy | Senior Vice President & Head of our Inflammation Therapeutic |
Michael Yee | Jefferies |
Brian Abrahams | RBC Capital Markets |
Geoff Meacham | Bank of America Merrill Lynch |
Geoff Porges | SVB Leerink |
Matthew Harrison | Morgan Stanley |
Alethia Young | Cantor Fitzgerald |
Umer Raffat | Evercore ISI |
Mohit Bansal | Citigroup |
Cory Kasimov | JPMorgan |
Salim Syed | Mizuho |
Phil Nadeau | Cowen & Company |
Evan Seigerman | Credit Suisse |
Tyler Van Buren | Piper Jaffray |
Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences' Third Quarter 2019 Earnings Conference Call. My name is Liz and I will be your conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded.
I would now like to turn the call over to Sung Lee, Senior Vice President of Investor Relations.